Amneal launches generic dexamethasone following anda approval by fda

Bridgewater, n.j.--(business wire)--amneal pharmaceuticals, inc. (nyse: amrx) (“amneal” or the “company”) today announced that it is launching dexamethasone, 4mg and 6 mg, following abbreviated new drug application (anda) approval from the u.s. food and drug administration (fda). dexamethasone, the generic version of decadron®, is a well-established anti-inflammatory glucocorticoid steroid used to treat several medical conditions, including respiratory complications associated with covid-19. “t
AMRX Ratings Summary
AMRX Quant Ranking